Vol 9, No 1 (2024)
Letter to the Editor
Published online: 2024-02-27

open access

Page views 123
Article views/downloads 144
Get Citation

Connect on Social Media

Connect on Social Media

Neurological implications of LONG-COVID-19 — current knowledge and the need for implementing remedies

Marta Graban1, Michal Pruc23, Francesco Chirico4, Lukasz Szarpak256, Damian Swieczkowski27, Sergiusz Blek8, Natasza Blek5
Disaster Emerg Med J 2024;9(1):60-61.


Not available


Disaster and Emergency Medicine Journal

2024, Vol. 9, No. 1, 60–61

DOI: 10.5603/demj.99169

Copyright © 2024 Via Medica

ISSN 2451–4691, e-ISSN 2543–5957

Neurological implications of LONG-COVID-19 — current knowledge and the need for implementing remedies

Marta Graban1Michal Pruc23Francesco Chirico4Lukasz Szarpak256Damian Swieczkowski27Sergiusz Blek8Natasza Blek5
1Department of Medical Informatics and Telemedicine, Medical University of Warsaw, Poland
2Department of Clinical Research and Development, LUXMED Group, Warsaw, Poland
3Department of Public Health, International European University, Kyiv, Ukraine
4Post-Graduate School of Occupational Health, Università Cattolica del Sacro Cuore, Rome, Italy
5Institute of Outcomes Research, Maria Sklodowska-Curie Medical Academy in Warsaw, Poland
6Maria Sklodowska-Curie Bialystok Oncology Centre, Bialystok, Poland
7Department of Toxicology, Faculty of Pharmacy, Medical University of Gdansk, Poland
8Research Unit, Polish Society of Disaster Medicine, Warsaw, Poland

Corresponding author:

Michal Pruc, Research Unit, Polish Society of Disaster Medicine, 05–806 Warsaw, Poland, e-mail: m.pruc@ptmk.org

Submitted: 29.01.2024 Accepted: 06.02.2024 Early publication date 27.02.2024

This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.

According to the Household Pulse Survey conducted by the Census Bureau, over 16.3 million individuals, which accounts for roughly 8% of working-age Americans, are now experiencing LONG-COVID-19. Out of the total number, around 2 to 4 million individuals are unemployed as a direct result of the long-term effects of COVID-19 [1]. Research conducted by Davis et al. [2] using data from 56 countries revealed that 22% of individuals suffering from LONG-COVID-19 had work incapacity as a result of their deteriorating health, while an additional 45% had to decrease their working hours. The prevalence of long-term and chronic neurological symptoms caused by COVID-19, often referred to as LONG-COVID-19, is attracting growing attention. These symptoms may last for many months or even years, impacting a significant number of individuals globally. LONG-COVID-19 often presents in previously asymptomatic persons, especially young adults, and may arise after a mild infection [3]. The most common, long-lasting, and debilitating symptoms of LONG-COVID-19 are related to the nervous system. A significant number of individuals experience fatigue and cognitive dysfunction, including decreased attention span, short-term memory loss, overall memory decline, language and motor skills impairment, decreased encoding and verbal fluency, and executive dysfunction [4]. Several symptoms that may be present include dysautonomia and postexertional malaise. Post-exertional malaise is a condition characterized by severe tiredness and depletion of energy that people experience even after little physical exertion. Dysautonomia, a disorder marked by impaired functioning of the autonomic nervous system, may present with symptoms such as dizziness, rapid heart rate, high or low blood pressure, and gastrointestinal irregularities [5]. The physiological processes underlying neurological symptoms caused by COVID-19 infection are currently being elucidated. In addition to previously believed long-lasting inflammatory mechanisms, immune dysregulation, microbiota disruption, autoimmunity, clotting and endothelial abnormality, and dysfunctional neurological signalling neuronal fusion is now considered a potential mechanism for the transmission and spread of the virus [6]. Preserving the distinctiveness of neurons is essential for the optimal operation of the nervous system. Studies suggest that COVID-19 might trigger the activation of viral fusogens, leading to the merging of brain cells in a way that cannot be reversed. This fusing of cells can disrupt the regular connection between neurons, thereby explaining how the infection can lead to neurological problems. The impact on neuronal fusion will be contingent upon the viral load in the brain and the particular regions infected. For SARS-CoV-2, the fusing of neurons that occurs when they are infected relies on the presence of ACE2, the virus’s cellular receptor, as well as other possible entry factors including TMPRSS2 and NRP1 in nearby neurons. Viruses like SARS-CoV-2 can induce the fusion of brain cells, which triggers aberrant behaviour and ultimately results in persistent neurological problems [7]. The administration of COVID-19 vaccines consistently decreased the likelihood of experiencing long-lasting symptoms of COVID-19, underscoring the significance of immunization in preventing persistent symptoms of the disease [8, 9]. The current Moderna and Pfizer-BioNTech vaccines include the whole S protein with two specific mutations spike S-2P. These mutations involve the insertion of two prolines at locations 986 and 987. The presence of prolines in the protein enhances its structural stability and prevents it from merging with other cells. The spike protein S-2P of the vaccine has been shown to completely lack the ability to fuse with neurons. This unequivocally showcases the efficacy and reliability of mRNA vaccines concerning their safety [10]. Furthermore, it is imperative to establish explicit protocols for the care and handling of individuals experiencing LONG-COVID-19, and to establish specialized institutions specifically designed for the treatment of this particular ailment.

Information and declarations
Author contributions

All authors contributed equally to the manuscript.

Conflict of interest



  1. National Center for Health Statistics. U.S. Census Bureau, Household Pulse Survey. https://www.cdc.gov/nchs/covid19/pulse/long-covid.htm (28.01.2024).
  2. Davis HE, Assaf GS, McCorkell L, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021; 38, doi: 10.1016/j.eclinm.2021.101019, indexed in Pubmed: 34308300.
  3. Ma Y, Deng J, Liu Q, et al. Long-Term Consequences of Asymptomatic SARS-CoV-2 Infection: A Systematic Review and Meta-Analysis. Int J Environ Res Public Health. 2023; 20(2), doi: 10.3390/ijerph20021613, indexed in Pubmed: 36674367.
  4. Zawilska JB, Kuczyńska K. Psychiatric and neurological complications of long COVID. J Psychiatr Res. 2022; 156: 349–360, doi: 10.1016/j.jpsychires.2022.10.045, indexed in Pubmed: 36326545.
  5. Vernon SD, Hartle M, Sullivan K, et al. Post-exertional malaise among people with long COVID compared to myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Work. 2023; 74(4): 1179–1186, doi: 10.3233/WOR-220581, indexed in Pubmed: 36911963.
  6. Davis HE, McCorkell L, Vogel JM, et al. Author Correction: Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023; 21(6): 408, doi: 10.1038/s41579-023-00896-0, indexed in Pubmed: 37069455.
  7. Martínez-Mármol R, Giordano-Santini R, Kaulich E, et al. SARS-CoV-2 infection and viral fusogens cause neuronal and glial fusion that compromises neuronal activity. Sci Adv. 2023; 9(23), doi: 10.1126/sciadv.adg2248, indexed in Pubmed: 37285437.
  8. Català M, Mercadé-Besora N, Kolde R, et al. The effectiveness of COVID-19 vaccines to prevent long COVID symptoms: staggered cohort study of data from the UK, Spain, and Estonia. Lancet Respir Med. 2024 [Epub ahead of print], doi: 10.1016/S2213-2600(23)00414-9, indexed in Pubmed: 38219763.
  9. Gozhenko A, Szarpak L, Jaguszewski M, et al. COVID-19 vaccine — third dose, booster dose? What is it and is it necessary? Disaster and Emergency Medicine Journal. 2021; 6(4): 208–209, doi: 10.5603/demj.a2021.0027.
  10. Hsieh CL, Goldsmith JA, Schaub JM, et al. Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. Science. 2020; 369(6510): 1501–1505, doi: 10.1126/science.abd0826, indexed in Pubmed: 32703906.

Disaster and Emergency Medicine Journal